An hs-CRP (high-sensitivity C-reactive protein) test measures the same liver protein as a standard CRP test but uses immunonephelometry to detect low-grade vascular inflammation down to 0.1 mg/L (versus 3.0 to 5.0 mg/L on a standard CRP). Cardiology guidelines classify hs-CRP below 1.0 mg/L as low risk, 1.0 to 3.0 mg/L as intermediate, and 2.0 mg/L or higher on repeat testing as a cardiovascular risk enhancer, while Fishtown Medicine targets below 0.7 mg/L alongside a Ferritin-to-CRP ratio of 6.1 or higher.
TL;DR:
- Same protein, finer assay: Standard CRP detects acute infections above 3.0 to 5.0 mg/L, while hs-CRP measures low-grade artery and tissue inflammation down to 0.1 mg/L.1
- Know the thresholds: Cardiology guidelines flag hs-CRP >= 2.0 mg/L on two quiet tests as a heart risk enhancer; Fishtown Medicine aims for < 0.7 mg/L and a Ferritin/CRP ratio >= 6.1.23
- LDL alone is not enough: In statin-treated patients, high hs-CRP doubled cardiovascular death risk (HR 2.68) even when LDL was well controlled (Ridker, Lancet 2023).4
- Test timing matters: Wait 2 to 3 weeks after a cold, vaccine, or dental work and skip hard workouts for 48 hours before your blood draw so a brief spike does not distort your baseline.5
How does an hs-CRP test differ from a standard CRP test and ESR?
An hs-CRP test measures the same C-reactive protein molecule as a standard CRP test, using a more sensitive laboratory assay calibrated for low concentrations (0.1 to 10.0 mg/L) instead of acute hospital inflammation.1
When fat tissue, irritated gums, or inflamed artery plaque release interleukin-6 (IL-6), your liver makes C-reactive protein and sends it into the bloodstream.1 Standard CRP panels are built to track major surges during pneumonia, appendicitis, or rheumatoid flares, so they lose precision below 3.0 to 5.0 mg/L. High-sensitivity assays (immunonephelometry or particle-enhanced immunoturbidimetry) close that blind spot so physicians can grade low-grade vascular risk.
| Blood Test or Ratio | What It Measures | Typical Lab Cutoff | Optimal Preventive Target | Best Clinical Use |
|---|---|---|---|---|
| hs-CRP | Low-grade hepatic CRP driven by IL-6 | < 1.0 mg/L low; >= 2.0 risk enhancer | < 0.7 mg/L | Heart risk stratification, statin/anti-inflammatory response |
| Standard CRP | Acute-phase hepatic CRP | < 5.0 to 10.0 mg/L | Useful only if > 5 mg/L | Acute infection, post-surgical monitoring, active autoimmune flare |
| ESR (Sed Rate) | Speed red blood cells settle (fibrinogen effect) | 0 to 20 mm/hr (varies by age/sex) | Low-normal | Polymyalgia rheumatica, temporal arteritis, bone/joint infections |
| GlycA | NMR composite of acute-phase glycoproteins | Lower quartile | Low-normal | Chronic metabolic/gut inflammation with less day-to-day swing |
| Ferritin / CRP Ratio | Iron stores divided by hs-CRP (mg/L) | Not flagged on standard labs | >= 6.1 | Separates true iron adequacy from inflammation-driven ferritin |
We also pair hs-CRP with ferritin using the Ferritin/CRP ratio. Because CRP and ferritin both rise during inflammation, a "normal" ferritin of 45 ng/mL alongside an hs-CRP of 4.0 mg/L yields a ratio of 11.2, whereas an inflamed ferritin of 60 ng/mL during a flare with hs-CRP of 12 mg/L masks depleted iron stores. If a high result already came back on your chart, see our follow-up triage steps in High CRP: What It Means.
What are the ACC/AHA hs-CRP risk tiers vs. the < 0.7 mg/L optimal target?
Cardiology guidelines define hs-CRP below 1.0 mg/L as low risk, 1.0 to 3.0 mg/L as intermediate risk, and 2.0 mg/L or higher as a cardiovascular risk enhancer, while Fishtown Medicine aims below 0.7 mg/L for optimal metabolic and vascular quiet.23
- Optimal Preventive Target (< 0.7 mg/L): Signals minimal IL-6 tone, low visceral fat signaling, and stable plaque biology.
- Borderline-High Watch Zone (0.7 to 1.0 mg/L): Above ideal longevity range. Often drops quickly with deeper sleep, gum care, or waist reduction.
- Clinical High Zone (1.0 to 1.9 mg/L): Mild systemic inflammation. Worth checking fasting insulin, oral estrogen use, and alcohol habits.
- Guideline Risk-Enhancer Zone (2.0 to 9.9 mg/L): The 2025 ACC Scientific Statement and 2026 ACC/AHA Dyslipidemia Guideline classify a persistent hs-CRP of 2.0 mg/L or higher (confirmed on two quiet draws at least two weeks apart) as an independent heart risk enhancer that favors starting or tightening lipid therapy.23
- Acute Surge (> 10.0 mg/L): Almost always reflects a short-term viral illness, sinus or tooth infection, vaccine reaction, or heavy tissue injury instead of chronic artery risk. Repeat the draw in 2 to 3 weeks and use the lower resting reading.5
C-reactive protein has a plasma half-life of roughly 19 hours once IL-6 signaling stops.1 Because its clearance is fixed regardless of health status, blood levels climb and fall smoothly as upstream triggers resolve.
Why does hs-CRP predict heart attacks even when LDL cholesterol is low?
Plaque rupture needs two ingredients: cholesterol particles entering the artery wall and white blood cells destabilizing the fibrous cap. Measuring hs-CRP alongside ApoB and Lp(a) catches silent vessel inflammation that a standard lipid panel misses.46
Large outcome trials established residual inflammatory risk as a direct driver of heart attacks and strokes:
- JUPITER Trial (Ridker et al., NEJM 2008; Lancet 2009): Enrolled 17,802 adults with normal LDL cholesterol (< 130 mg/dL) and hs-CRP >= 2.0 mg/L. Rosuvastatin 20 mg cut major cardiovascular events by 44% overall, and patients who reached both LDL < 70 mg/dL and hs-CRP < 1.0 mg/L saw the largest risk drop.7
- Statin-Treated Meta-Analysis (Ridker et al., Lancet 2023): Across 31,245 patients already taking modern statins, residual hs-CRP predicted cardiovascular death (HR 2.68) and all-cause mortality (HR 2.42) more strongly than residual LDL cholesterol.4
- 30-Year Women's Health Study (Ridker et al., NEJM 2024): Among 27,939 initially healthy women followed for 30 years, baseline hs-CRP in the top fifth raised long-term heart and stroke risk (HR 1.70) independently of LDL cholesterol and Lp(a). Combining high hs-CRP, high LDL, and high Lp(a) pushed 30-year event risk 2.6-fold higher.6
- Pure Anti-Inflammatory Proof (CANTOS, COLCOT, LoDoCo2): Canakinumab (an IL-1beta antibody in CANTOS) and low-dose colchicine 0.5 mg (COLCOT and LoDoCo2) cut recurrent heart attacks without lowering LDL by a single point, proving vascular inflammation is a causal target.89
Fishtown Medicine
A 90-minute conversation with Dr. Ash. A written plan you can follow.
In contrast with Lp-PLA2, which acts inside inflamed plaque macrophages along the artery wall, hs-CRP reflects whole-body IL-6 signaling and remains the primary guideline biomarker.
How should you prepare for an hs-CRP blood draw so a workout or cold does not skew it?
Fasting is not required for hs-CRP alone, though it is usually drawn fasting alongside ApoB, triglycerides, and insulin. Hold intense workouts for 48 hours and delay the draw 2 to 3 weeks after any cold, infection, or dental procedure.5
- Rest your muscles for 48 hours: Heavy eccentric lifting, long endurance runs (> 60 to 90 minutes), and downhill sprints tear muscle fibers and release muscle IL-6, briefly doubling hs-CRP for 1 to 3 days.
- Respect recent illnesses and dental work: Even a mild head cold, sinus flare, sore tooth, or deep dental cleaning can bump hs-CRP above 3.0 to 10.0 mg/L. Wait 14 to 21 days after full recovery before testing.
- Note oral estrogen therapy: Oral estrogen pills undergo first-pass liver metabolism and can nearly double CRP (+192% in head-to-head studies), while transdermal estradiol patches have near-zero effect on CRP.10
- Take two baseline draws if borderline: Because single-sample biological noise occurs in roughly one-third of borderline draws, confirm any reading >= 1.5 to 2.0 mg/L on a second quiet morning 2 weeks later before labeling it your true baseline.5
Guidance from the Clinic
Key Takeaways
- Order hs-CRP, not standard CRP, for preventive care: Standard CRP misses risk below 3.0 mg/L, whereas hs-CRP measures vascular inflammation down to 0.1 mg/L.1
- Aim for < 0.7 mg/L on two quiet draws: Cardiology guidelines use >= 2.0 mg/L as a risk enhancer, and Fishtown Medicine targets < 0.7 mg/L plus a Ferritin/CRP ratio >= 6.1.23
- Pair hs-CRP with ApoB and Lp(a): The 30-year Women's Health Study proved all three markers add independent predictive power for decades.6
- Prepare before the blood draw: Skip hard exercise for 48 hours, wait 2 to 3 weeks after any illness or dental procedure, and flag oral estrogen use.510
Related at Fishtown Medicine
- High CRP: What It Means and How to Lower It
- 9-System Biomarker Reference Guide
- Low-Dose Colchicine for Cardiovascular Prevention
- ApoB and Heart Health
- Lipoprotein(a) Testing and Treatment
- Lp-PLA2 (the PLAC Test) and Vascular Inflammation
- Understanding Insulin Resistance
Scientific References
- Ridker PM. "A Test in Context: High-Sensitivity C-Reactive Protein." Journal of the American College of Cardiology. 2016;67(6):712-723.
- Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. "Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement." Journal of the American College of Cardiology. 2025.
- Blumenthal RS, Morris PB, Gaudino M, et al. "2026 ACC/AHA Guideline on the Management of Dyslipidemia." Journal of the American College of Cardiology. 2026.
- Ridker PM, Bhatt DL, Pradhan AD, et al. "Inflammation and Cholesterol as Predictors of Cardiovascular Events Among Patients Receiving Statin Therapy." Lancet. 2023;401(10384):1293-1301.
- DeGoma EM, French B, Dunbar RL, et al. "Intraindividual Variability of C-Reactive Protein: The Multi-Ethnic Study of Atherosclerosis." Atherosclerosis. 2012;224(1):274-279.
- Ridker PM, Moorthy MV, Cook NR, et al. "Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women." New England Journal of Medicine. 2024;391(22):2087-2097.
- Ridker PM, Danielson E, Fonseca FA, et al. "Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein (JUPITER)." New England Journal of Medicine. 2008;359(21):2195-2207.
- Ridker PM, Everett BM, Thuren T, et al. "Antiinflammatory Therapy With Canakinumab for Atherosclerotic Disease (CANTOS)." New England Journal of Medicine. 2017;377(12):1119-1131.
- Nidorf SM, Fiolet ATL, Mosterd A, et al. "Colchicine in Patients With Chronic Coronary Disease (LoDoCo2)." New England Journal of Medicine. 2020;383(19):1838-1847.
- Shifren JL, Rifai N, Desindes S, et al. "Oral Conjugated Equine Estrogens Versus Transdermal Estradiol on C-Reactive Protein." Journal of Clinical Endocrinology & Metabolism. 2008;93(5):1702-1710.
Frequently Asked Questions
Common Questions
Deep-Dive Questions
Ready when you are
The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.





